Literature DB >> 21472111

Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.

Shi-Yan Yan1, Ying Hu, Jian-Gao Fan, Guo-Quan Tao, Yong-Ming Lu, Xu Cai, Bao-Hua Yu, Yi-Qun Du.   

Abstract

AIM: To study the HER-2/neu protein expression and gene amplification in gastric carcinoma and their relation.
METHODS: One hundred and forty-five formalin-fixed and paraffin- embedded tumor tissue samples from Chinese gastric carcinoma patients were studied with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) methods. Clinicopathologic data about all patients were collected.
RESULTS: The levels of HER-2 3+, HER-2 2+ and HER2 1+ were measurable in 6.9%, 8.3% and 17.2% of the samples, respectively. No HER-2 was stained in 67.6% of the samples. FISH showed that HER-2 gene was amplified in 18 samples, 10 HER-2 3+ samples, 5 HER-2 2+ samples, and 3 HER-2 1+ samples with IHC staining. HER-2 status was not correlated with the sex and age of patients, and tumor size, location or differentiation, but with the depth of invasion, TNM stage, lymph node and distant metastasis as well as histopathological classification of gastric cancer (P < 0.05).
CONCLUSION: All samples with IHC as HER-2 expression should be analyzed with FISH. Detection of HER-2 gene amplification can assess the malignant biological behaviors and prognosis of gastric cancer.

Entities:  

Keywords:  Clinocopathologic significance; Fluorescence in situ hybridization; Gastric carcinoma; HER-2; Immunohistochemistry

Mesh:

Substances:

Year:  2011        PMID: 21472111      PMCID: PMC3070026          DOI: 10.3748/wjg.v17.i11.1501

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

Review 1.  The discovery of receptor tyrosine kinases: targets for cancer therapy.

Authors:  Andreas Gschwind; Oliver M Fischer; Axel Ullrich
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.

Authors:  H Allgayer; R Babic; K U Gruetzner; A Tarabichi; F W Schildberg; M M Heiss
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

3.  Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database.

Authors:  D A Corley; P A Buffler
Journal:  Int J Epidemiol       Date:  2001-12       Impact factor: 7.196

4.  Evaluation of the epidermal growth factor receptor (EGFR) and c-erbB-2 in superspreading-type and penetrating-type gastric carcinoma.

Authors:  K Aoyagi; K Kohfuji; S Yano; N Murakami; M Miyagi; J Takeda; K Shirouzu
Journal:  Kurume Med J       Date:  2001

5.  No association between HER-2 gene polymorphism at codon 655 and a risk of bladder cancer.

Authors:  Lizhong Wang; Tomonori Habuchi; Takeshi Takahashi; Toshiyuki Kamoto; Tao Zuo; Kenji Mitsumori; Norihiko Tsuchiya; Kazunari Sato; Osamu Ogawa; Tetsuro Kato
Journal:  Int J Cancer       Date:  2002-02-20       Impact factor: 7.396

6.  Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay.

Authors:  Takuo Takehana; Kazuyoshi Kunitomo; Koji Kono; Fumiaki Kitahara; Hidehiko Iizuka; Yoshiro Matsumoto; Masayuki A Fujino; Akishi Ooi
Journal:  Int J Cancer       Date:  2002-04-20       Impact factor: 7.396

7.  Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.

Authors:  Estrid V S Høgdall; Lise Christensen; Susanne K Kjaer; Jan Blaakaer; Johannes E Bock; Eva Glud; Bent Nørgaard-Pedersen; Claus K Høgdall
Journal:  Cancer       Date:  2003-07-01       Impact factor: 6.860

8.  HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.

Authors:  Josef Rüschoff; Manfred Dietel; Gustavo Baretton; Susanne Arbogast; Axel Walch; Geneviéve Monges; Marie-Pierre Chenard; Frédérique Penault-Llorca; Iris Nagelmeier; Werner Schlake; H Höfler; H H Kreipe
Journal:  Virchows Arch       Date:  2010-07-28       Impact factor: 4.064

9.  Prognostic significance of p53, nm23, PCNA and c-erbB-2 in gastric cancer.

Authors:  Kyu Eun Lee; Hyuk-Joon Lee; Yoon Ho Kim; Hang Jong Yu; Han-Kwang Yang; Woo-Ho Kim; Kuhn Uk Lee; Kuk Jin Choe; Jin-Pok Kim
Journal:  Jpn J Clin Oncol       Date:  2003-04       Impact factor: 3.019

10.  Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000.

Authors:  Kenji Shibuya; Colin D Mathers; Cynthia Boschi-Pinto; Alan D Lopez; Christopher J L Murray
Journal:  BMC Cancer       Date:  2002-12-26       Impact factor: 4.430

View more
  35 in total

1.  Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis.

Authors:  Jennifer Jeung; Roshan Patel; Lizette Vila; Dara Wakefield; Chen Liu
Journal:  Arch Pathol Lab Med       Date:  2012-06       Impact factor: 5.534

2.  Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor.

Authors:  Sang-Woo Lim; Hye-Ran Kim; Hwan-Young Kim; Jung-Wook Huh; Young-Jin Kim; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang; Hyeong-Rok Kim; Myung-Geun Shin
Journal:  Cell Oncol (Dordr)       Date:  2013-05-31       Impact factor: 6.730

3.  Are biopsy specimens predictive of HER2 status in gastric cancer patients?

Authors:  M Pirrelli; M L Caruso; M Di Maggio; R Armentano; A M Valentini
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

4.  An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma.

Authors:  Zongqiong Sun; Xiaofang Cheng; Yuxi Ge; Lin Shao; Yinghua Xuan; Gen Yan
Journal:  Gastric Cancer       Date:  2017-09-04       Impact factor: 7.370

5.  Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.

Authors:  Byung Woog Kang; Dakeun Lee; Ho Young Chung; Jae Ho Han; Young-Bae Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-05       Impact factor: 4.553

Review 6.  Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies.

Authors:  Michael Luis; Ana Tavares; Liliana S Carvalho; Lúcio Lara-Santos; António Araújo; Ramon Andrade de Mello
Journal:  World J Gastroenterol       Date:  2013-10-14       Impact factor: 5.742

7.  HER2 expression and its clinicopathological features in resectable gastric cancer.

Authors:  Yoshiki Kataoka; Hiroshi Okabe; Akihiko Yoshizawa; Sachiko Minamiguchi; Kenichi Yoshimura; Hironori Haga; Yoshiharu Sakai
Journal:  Gastric Cancer       Date:  2012-03-14       Impact factor: 7.370

8.  An independent survival prognostic role for human epidermal growth factor receptor 2 in gastric cancer: evidence from a meta-analysis.

Authors:  Y Wang; L He; Y Cheng
Journal:  Clin Transl Oncol       Date:  2017-07-05       Impact factor: 3.405

9.  Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.

Authors:  Chao He; Xue-Yi Bian; Xing-Zhi Ni; Dan-Ping Shen; Yan-Ying Shen; Hua Liu; Zhi-Yong Shen; Qiang Liu
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

10.  Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.

Authors:  Sadaf Farzand; Tahir Siddique; Kanwal Saba; Mulazim Hussain Bukhari
Journal:  World J Gastroenterol       Date:  2014-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.